| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_33b011e77b33662b8bf1f2ff2de7b661 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C271-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D261-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6899
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0804
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-101 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D261-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C271-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-083
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-103
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
| filingDate |
1981-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6401793b0fc599144f7045d7fc8a43f7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4970f8000f3f2a21840a7e83c2f60cf0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80829d0980d22d2078becf7077df5ffb |
| publicationDate |
1981-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0038357-A1 |
| titleOfInvention |
Hydrolytic enzyme-activatible pro-drugs |
| abstract |
Anti-neoplast agents are made specific for tumors by derivation using a peptide specificator so as to convert the anti-neoplast agent into a pharmacologically inert pro-drug which can be selectively active where the tumor appears. The peptide specificator has a sequence of amino acid residues allowing it to be separated enzymatically and selectively from the anti-neoplast agent by fibrinolitic proteases associated with the tumor and / or blood coagulation, such as plasmin and plasminogen activator to effect release of the anti-neoplate agent in pharmacologically active form in the vicinity of the tumor. These and similar drugs which can be activated by hydrolytic enzymes can be formed with their specifier half and their half covalently linked together through a self-destructing intermediate connection half having molecular structure such that the enzymatic cleavage of the covalent bond to the half specifier will start the spontaneous cleavage of the covalent bond to the half drug to thereby effect the release of the drug in a pharmacologically active form. |
| priorityDate |
1979-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |